Dr. Sigrun Hope, MD, PhD - Oslo University Hospital, Department og Neurohabilitation - Senior consultant (Overlege)

Dr. Sigrun Hope

MD, PhD

Oslo University Hospital, Department og Neurohabilitation

Senior consultant (Overlege)

Oslo, Velg | Norway

Additional Specialties: Neurodevelopmental disorders

ORCID logohttps://orcid.org/0000-0003-0115-5285

Dr. Sigrun Hope, MD, PhD - Oslo University Hospital, Department og Neurohabilitation - Senior consultant (Overlege)

Dr. Sigrun Hope

MD, PhD

Introduction

Primary Affiliation: Oslo University Hospital, Department og Neurohabilitation - Oslo, Velg , Norway

Additional Specialties:

Research Interests:

Metrics

Number of Publications

42

Publications

Number of Profile Views

79

Profile Views

Number of Article Reads

218

Reads

Number of Citations

139

Citations

Education

May 2012
PhD
University of Oslo
May 2012
PhD
University of Oslo
Jan 2008 - Jan 2012
University of Oslo
PhD
Jan 1985 - Jan 1992
University of Oslo
MD

Experience

Jan 2014
University of Oslo
Postdoc
Jan 2011
Oslo university Hospital
Overlege / MD senior consultant

Top co-authors

Ole A Andreassen
Ole A Andreassen

Institute of Clinical Medicine

19
Ingrid Melle
Ingrid Melle

Institute of Clinical Medicine

17
Thor Ueland
Thor Ueland

Oslo University Hospital

13
Ingrid Dieset
Ingrid Dieset

Oslo University Hospital Ullevål

13
Ingrid Agartz
Ingrid Agartz

University of Oslo

13
Srdjan Djurovic
Srdjan Djurovic

Oslo University Hospital

10
Nils Eiel Steen
Nils Eiel Steen

Oslo University Hospital

10
Steinar Lorentzen
Steinar Lorentzen

Institute of Clinical Medicine

6

Publications

42Publications

218Reads

139PubMed Central Citations

Securing rights and nutritional health for persons with intellectual disabilities - a pressing challenge.

Food Nutr Res 2018 7;62. Epub 2018 Jun 7.

Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.

View Article
June 2018
5 Reads

Side effect burden of antipsychotic drugs in real life - Impact of gender and polypharmacy.

Prog Neuropsychopharmacol Biol Psychiatry 2018 03 7;82:263-271. Epub 2017 Nov 7.

NORMENT K.G. Jebsen Center for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo University Hospital, Oslo, Norway; Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet, Stockholm, Sweden.

View Article
March 2018
12 Reads
1 Citation
3.690 Impact Factor

Exploring the Wnt signaling pathway in schizophrenia and bipolar disorder.

Transl Psychiatry 2018 03 6;8(1):55. Epub 2018 Mar 6.

Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.

View Article
March 2018
3 Reads
4.360 Impact Factor

Childhood maltreatment severity is associated with elevated C-reactive protein and body mass index in adults with schizophrenia and bipolar diagnoses.

Brain Behav Immun 2017 Oct 13;65:342-349. Epub 2017 Jun 13.

NORMENT K.G Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, Norway.

View Article
October 2017
18 Reads
2 Citations
5.890 Impact Factor

Event-Related Potentials in a Cued Go-NoGo Task Associated with Executive Functions in Adolescents with Autism Spectrum Disorder; A Case-Control Study.

Front Neurosci 2017 11;11:393. Epub 2017 Jul 11.

Norwegian Centre for Mental Disorders, KG Jebsen Centre for Psychosis Research, University of OsloOslo, Norway.

View Article
July 2017
11 Reads

Parents' Attitudes toward Clinical Genetic Testing for Autism Spectrum Disorder-Data from a Norwegian Sample.

Int J Mol Sci 2017 May 18;18(5). Epub 2017 May 18.

NORMENT, KG Jebsen Centre for Psychosis Research, University of Oslo, Oslo 0424, Norway.

View Article
May 2017
47 Reads
2.860 Impact Factor

Low vitamin D is associated with negative and depressive symptoms in psychotic disorders.

Schizophr Res 2016 12 29;178(1-3):44-49. Epub 2016 Aug 29.

NORMENT, K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway. Electronic address:

View Article
December 2016
21 Reads
4 Citations
3.920 Impact Factor

Inflammatory evidence for the psychosis continuum model.

Psychoneuroendocrinology 2016 May 17;67:189-97. Epub 2016 Feb 17.

NORMENT, KG Jebsen Centre for Psychosis Research, University of Oslo and Oslo University Hospital, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Ullevål, Oslo, Norway.

View Article
May 2016
8 Reads
3 Citations
4.940 Impact Factor

The investigation of inborn errors of metabolism as an underlying cause of idiopathic intellectual disability in adults in Norway.

Eur J Neurol 2016 Jan;23 Suppl 1:36-44

Department of Clinical Neurosciences for Children, Women and Children's Division, Oslo University Hospital, Ullevål, Oslo, Norway.

View Article
January 2016
1 Read
4.050 Impact Factor

Inflammatory markers are associated with general cognitive abilities in schizophrenia and bipolar disorder patients and healthy controls.

Schizophr Res 2015 Jul 5;165(2-3):188-94. Epub 2015 May 5.

NORMENT, KG Jebsen Centre for Psychosis Research, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Ullevål, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

View Article
July 2015
8 Reads
9 Citations
3.920 Impact Factor

Association between altered brain morphology and elevated peripheral endothelial markers--implications for psychotic disorders.

Schizophr Res 2015 Feb 27;161(2-3):222-8. Epub 2014 Nov 27.

KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

View Article
February 2015
17 Reads
4 Citations
3.920 Impact Factor

Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder.

Schizophr Res 2013 Apr 8;145(1-3):36-42. Epub 2013 Feb 8.

KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

View Article
April 2013
2 Reads
18 Citations
3.920 Impact Factor

Up-regulation of NOTCH4 gene expression in bipolar disorder.

Dieset I, Djurovic S, Tesli M, Hope S, Mattingsdal M, Michelsen A, Joa I, Larsen TK, Agartz I, Melle I, Røssberg JI, Aukrust P, Andreassen OA, Ueland T, The American journal of psychiatry, 2012, vol. 169, no. 12, pp. 1292-1300

http://europepmc.org/abstract/med/23212060

View Article
2012

Up-regulation of NOTCH4 gene expression in bipolar disorder.

Am J Psychiatry 2012 Dec;169(12):1292-300

Division of Mental Health and Addiction, Oslo University Hospital Ullevål, Oslo, Norway.

View Article
December 2012
5 Reads
7 Citations
12.290 Impact Factor

Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein.

Dieset I, Hope S, Ueland T, Bjella T, Agartz I, Melle I, Aukrust P, Røssberg JI, Andreassen OA, Schizophrenia research, 2012, vol. 140, no. 1-3, pp. 169-174

http://europepmc.org/abstract/med/22817875

View Article
October 2012

Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein.

Schizophr Res 2012 Sep 18;140(1-3):169-74. Epub 2012 Jul 18.

Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

View Article
September 2012
2 Reads
9 Citations
3.920 Impact Factor

Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia.

Hope S, Dieset I, Agartz I, Steen NE, Ueland T, Melle I, Aukrust P, Andreassen OA, Journal of psychiatric research, 2011, vol. 45, no. 12, pp. 1608-1616

http://europepmc.org/abstract/med/21889167

View Article
2011

Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia.

J Psychiatr Res 2011 Dec 1;45(12):1608-16. Epub 2011 Sep 1.

Department of Psychiatry, Østfold Hospital, Fredrikstad, Norway.

View Article
December 2011
2 Reads
26 Citations
3.960 Impact Factor

Increased systemic cortisol metabolism in patients with schizophrenia and bipolar disorder: a mechanism for increased stress vulnerability?

Steen NE, Methlie P, Lorentzen S, Hope S, Barrett EA, Larsson S, Mork E, Almås B, Løvås K, Agartz I, Melle I, Berg JP, Andreassen OA, The Journal of clinical psychiatry, 2011, vol. 72, no. 11, pp. 1515-1521

http://europepmc.org/abstract/med/21367348

View Article
December 2011

Increased systemic cortisol metabolism in patients with schizophrenia and bipolar disorder: a mechanism for increased stress vulnerability?

J Clin Psychiatry 2011 Nov 8;72(11):1515-21. Epub 2011 Feb 8.

Section for Psychosis Research, Clinic of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

View Article
November 2011
18 Reads
10 Citations
5.500 Impact Factor

Sex-specific cortisol levels in bipolar disorder and schizophrenia during mental challenge--relationship to clinical characteristics and medication.

Steen NE, Lorentzen S, Barrett EA, Lagerberg TV, Hope S, Larsson S, Berg AO, Agartz I, Melle I, Berg JP, Andreassen OA, Progress in neuro-psychopharmacology & biological psychiatry, 2011, vol. 35, no. 4, pp. 1100-1107

http://europepmc.org/abstract/med/21420462

View Article
July 2011

Sex-specific cortisol levels in bipolar disorder and schizophrenia during mental challenge--relationship to clinical characteristics and medication.

Prog Neuropsychopharmacol Biol Psychiatry 2011 Jun 21;35(4):1100-7. Epub 2011 Mar 21.

Psychosis Research Unit, Division of Mental Health and Addiction, Oslo University Hospital, Ullevål Hospital, P.O. Box 4956 Nydalen, 0424 Oslo, Norway.

View Article
June 2011
1 Read
4 Citations
3.690 Impact Factor

SRD5A2 is associated with increased cortisol metabolism in schizophrenia spectrum disorders.

Steen NE, Tesli M, Kähler AK, Methlie P, Hope S, Barrett EA, Larsson S, Mork E, Løvås K, Røssberg JI, Agartz I, Melle I, Djurovic S, Lorentzen S, Berg JP, Andreassen OA, Progress in neuro-psychopharmacology & biological psychiatry, 2010, vol. 34, no. 8, pp. 1500-1506

http://europepmc.org/abstract/med/20800085

View Article
2010

SRD5A2 is associated with increased cortisol metabolism in schizophrenia spectrum disorders.

Prog Neuropsychopharmacol Biol Psychiatry 2010 Dec 25;34(8):1500-6. Epub 2010 Aug 25.

Section for Psychosis Research, Clinic of Mental Health and Addiction, Oslo University Hospital, Ullevål Hospital, P.O. Box 4956 Nydalen, 0424 Oslo, Norway.

View Article
December 2010
5 Reads
5 Citations
3.690 Impact Factor

Osteoprotegerin levels in patients with severe mental disorders.

Hope S, Melle I, Aukrust P, Agartz I, Lorentzen S, Steen NE, Djurovic S, Ueland T, Andreassen OA, Journal of psychiatry & neuroscience : JPN, 2010, vol. 35, no. 5, pp. 304-310

http://europepmc.org/abstract/med/20569643

View Article
October 2010

Osteoprotegerin levels in patients with severe mental disorders.

J Psychiatry Neurosci 2010 Sep;35(5):304-10

Department of Psychiatry, Østfold Hospital, Fredrikstad, Norway.

View Article
September 2010
1 Read
2 Citations
5.860 Impact Factor

Top co-authors

Ole A Andreassen
Ole A Andreassen

Institute of Clinical Medicine

19
Ingrid Melle
Ingrid Melle

Institute of Clinical Medicine

17
Thor Ueland
Thor Ueland

Oslo University Hospital

13
Ingrid Dieset
Ingrid Dieset

Oslo University Hospital Ullevål

13
Ingrid Agartz
Ingrid Agartz

University of Oslo

13
Srdjan Djurovic
Srdjan Djurovic

Oslo University Hospital

10
Nils Eiel Steen
Nils Eiel Steen

Oslo University Hospital

10
Steinar Lorentzen
Steinar Lorentzen

Institute of Clinical Medicine

6